Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Mark Mulligan and Philip Dormitzer.
Mark Mulligan
Connection Strength
0.513
Philip Dormitzer
  1. Publisher Correction: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2021 Feb; 590(7844):E26.
    View in: PubMed
    Score: 0.232
  2. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020 10; 586(7830):589-593.
    View in: PubMed
    Score: 0.224
  3. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med. 2020 12 17; 383(25):2439-2450.
    View in: PubMed
    Score: 0.057
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.